生物技术公司ImmunityBio（IBRX）在夜盘交易中股价大跌5.51%，主要原因是公司公布的季度财报低于市场预期。
根据ImmunityBio发布的最新财务报告，截至3月31日的季度调整后每股亏损为15美分，高于分析师平均预期的13美分亏损。尽管公司营收同比大幅增长41192.5%，达到1652万美元，超过分析师预期的1602万美元，但当季净亏损仍高达1.2965亿美元。这一业绩表现显示公司在快速增长的同时，仍面临着巨大的成本压力。
值得注意的是，过去30天内已有两位分析师下调了对该公司的盈利预测，反映出市场对公司短期盈利能力的担忧。尽管如此，华尔街分析师对ImmunityBio的总体评级仍维持在"买入"水平，12个月目标价中位数为8.00美元。这表明尽管公司短期业绩不佳，但长期发展前景仍被看好。投资者可能需要权衡公司的长期潜力和短期财务压力，以做出投资决策。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.